Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Semaglutide improves kidney and cardiovascular outcomes in diabetes
Última actualización 6 de julio de 2026
Key finding
Semaglutide reduced the risk of the primary kidney outcome by 49% (HR 0.51 [95% CI 0.30, 0.86]) versus placebo.
This study evaluated the impact of semaglutide on kidney and cardiovascular risks in individuals with type 2 diabetes and chronic kidney disease, finding significant reductions in key health outcomes.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the impact of semaglutide on kidney and cardiovascular risks in individuals with type 2 diabetes and chronic kidney disease, finding significant reductions in key health outcomes.
Clinical relevance
These findings are clinically significant as they suggest that semaglutide can improve health outcomes for patients with type 2 diabetes and chronic kidney disease, a population at high risk for cardiovascular events and kidney failure. By effectively reducing these risks, semaglutide may enhance patient quality of life and reduce healthcare costs associated with complications.
Keep in mind
The study may have limited generalizability due to specific inclusion criteria. Potential unmeasured confounders may affect the results. The long-term effects of semaglutide were not fully assessed.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Peter R, George B, Vlado P, et al. Semaglutide Reduces Kidney and Cardiovascular Risks in Type 2 Diabetes with Chronic Kidney Disease. Diabetes Care. 2025;48(11):1878-1887. doi:10.2337/dc25-0472
Efectos Principales
Semaglutide reduced the risk of the primary kidney outcome by 49% compared to placebo.
Semaglutide showed consistent benefits on major adverse cardiovascular events.
Semaglutide reduced the risk of all-cause mortality.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Semaglutide and Albuminuria, All-cause mortality, Composite cardiovascular events (CV death, MI, stroke, HF hospitalization), and 2 more.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
- Albuminuria
- All-cause mortality
- Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
5
Evidence pairs
5
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
2
Related topics
5
Evidence pairs
120
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 5 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
GLP-1 Receptor Agonists and Cardiovascular Outcomes
Evidencia relacionada
Relación de evidencia
GLP-1 Receptor Agonists and Kidney Function
Guardar evidencia
Tema de evidencia
Cardiovascular Risk
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- 82
- Strong
- ImpactScore™
- 64
- Slightly Positive
- ConsistencyScore™
- 57
- generally_consistent
Estudios de apoyo: Basado en 7 estudios
Add to Evidence TrackerComposite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Semaglutide → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Semaglutide → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 86
- Very Positive
- ConsistencyScore™
- 71
- generally_consistent
Estudios de apoyo: Basado en 7 estudios
Add to Evidence TrackerEstimated glomerular filtration rate
Semaglutide → Estimated glomerular filtration rate
Semaglutide → Estimated glomerular filtration rate
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 35
- mixed
Estudios de apoyo: Basado en 2 estudios
Add to Evidence TrackerMajor kidney disease events composite including kidney or cardiovascular death
Semaglutide → Major kidney disease events composite including kidney or cardiovascular death
Semaglutide → Major kidney disease events composite including kidney or cardiovascular death
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Semaglutide reduced primary kidney outcomes by 49% (HR 0.51).
- Albuminuria decreased by 33% in nonusers of semaglutide.
- Placebo did not show significant reductions in any measured outcomes.
A quién se aplica
- Adults with type 2 diabetes.
- Patients with chronic kidney disease.
Tener en Cuenta
- Results may not apply to populations outside the study criteria.
- The study's duration may not capture long-term effects.
- Further research is needed to confirm these findings in diverse populations.
Entre Líneas
- The study may have limited generalizability due to specific inclusion criteria.
- Potential unmeasured confounders may affect the results.
- The long-term effects of semaglutide were not fully assessed.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Cardiovascular Outcomes, GLP-1 Receptor Agonists and Cardiovascular Outcomes.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 86
- Very Positive
- ConsistencyScore™
- 71
- generally_consistent
Estudios de apoyo: Basado en 7 estudios
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- 82
- Strong
- ImpactScore™
- 64
- Slightly Positive
- ConsistencyScore™
- 57
- generally_consistent
Estudios de apoyo: Basado en 7 estudios
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Cardiovascular Outcomes Evidence Hub
All studies measuring Cardiovascular Outcomes
7 studies
outcome_hubMeasures Cardiovascular Outcomes as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
7 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Semaglutide and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Intervention: SemaglutideOutcome: Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
7 results
All studies on Semaglutide and All-cause mortality
Intervention: SemaglutideOutcome: All-cause mortality
7 results
All studies on Semaglutide
Intervention: Semaglutide
7 results
All studies measuring Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Outcome: Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
7 results
All studies measuring All-cause mortality
Outcome: All-cause mortality
7 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Do GLP-1 Receptor Agonists improve cardiovascular outcomes?
Strong Evidence
GLP-1 Receptor Agonists may improve cardiovascular outcomes.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
EvidenceScore™ Strong | EvidenceScore™ 83.2 | strong positive | ConsistencyScore™ Generally Consistent | 1 study
- 2
All-cause mortality
EvidenceScore™ Strong | EvidenceScore™ 82.3 | weak positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 13 supporting studies with consistent results and a positive effect signal.
Do GLP-1 Receptor Agonists improve kidney function?
Strong Evidence
GLP-1 Receptor Agonists may improve kidney function.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Estimated glomerular filtration rate
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Mixed | 1 study
- 2
Albuminuria
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Does Semaglutide improve major kidney disease events composite including kidney or cardiovascular death?
Emerging Evidence
Semaglutide appears to improve major kidney disease events composite including kidney or cardiovascular death.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Major kidney disease events composite including kidney or cardiovascular death
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
All studies on Semaglutide and Major kidney disease events composite including kidney or cardiovascular deathAll studies on Semaglutide and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)All studies on Semaglutide and All-cause mortalityAll studies on Semaglutide and Estimated glomerular filtration rate
Related research
Read related research summaries.
Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesSemaglutide improves insulin sensitivity in adolescents with obesityHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic Control
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.